Could nanotech tattoos be the future of health monitoring?
Researchers in South Korea have developed an electronic tattoo that automatically signals potential health issues.
Researchers at the Korea Advanced Institute of Science and Technology (KAIST) in the city of Daejeon have developed an electronic tattoo ink made of liquid metal and carbon nanotubes that can help monitor heart rates and other vital health signs.
The ink works by effectively creating an electric circuit on the skin. When connected to an electrocardiogram (ECG) device or other biosensor, it can send a readout of a patient's heart rate and other vital signs such glucose and lactate to a monitor. The current technology is limited by the fact that it still requires wiring to acquire data, an issue researchers hope to address in the future.
Project leader, Steve Park, told Reuters: ‘In the future, what we hope to do is connect a wireless chip integrated with this ink, so that we can communicate, or we can send signal back and forth between our body to an external device.’
Such monitors could be located in patients’ homes. The tattoo ink is made from particles based on gallium, a metal also used in semiconductors or thermometers. Platinum-decorated carbon nanotubes help conduct electricity while providing durability.
‘When it is applied to the skin, even with rubbing the tattoo doesn't come off, which is not possible with just liquid metal,’ Park added. The ink does come off with soap and dries on the skin in less than 10 seconds.
Related News
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile... -
News Eli Lilly eyes India as next global export hub
Eli Lilly and Co. is positioning India as a key player in its global supply chain, driven by the booming success of its diabetes and obesity drug, Mounjaro.
-
News Women in Pharma: Quality leadership, quality services
Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive. -
News WuXi Biologics accomplishes automated continuous drug substance production at pilot-scale
Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale.
-
News Women in Pharma: A Place to Share Worries and Challenges - CPHI Women in CPHI Japan
This year’s CPHI Women event was held on 10 April 2025 inside the CPHI Japan venue adjacent to Tokyo Big Sight. Now in its 9th edition, CPHI Women aims to foster networking opportunities for women working in the pharmaceutical industry in Japan. -
News EU Commission to restrict Chinese companies in medical devices procurement
The European Commission, the primary executive arm of the EU, announced their decision to exclude Chinese companies from EU government purchases of medical devices exceeding EUR€5 million in a bid to rebalance trade barriers.